AKBA vs APUS: Side-by-Side Comparison
Compare Akebia Therapeutics Inc (AKBA) and Apimeds Pharmaceuticals US Inc (APUS) side by side: market cap USD 332.64M vs USD 13.58M. Financials, growth and model signals on Bullrun.
| Metric | AKBA | APUS |
|---|---|---|
| Company | Akebia Therapeutics Inc | Apimeds Pharmaceuticals US Inc |
| Country / Exchange | United States · NASDAQ | United States · NYSE MKT |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers-Specialty & Generic | Drug Manufacturers-Specialty & Generic |
| Market cap | USD 332.64M | USD 13.58M |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Valuation model | — | — |
| Revenue (FY2025) | USD 236.20M | — |
| Revenue growth YoY | +47.5% | — |
| Net income | USD -5.30M | USD -6.00M |
| Gross margin | 83.3% | — |
| Diluted EPS | -0.02 | -0.55 |